Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.35 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.35 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
| ▸ | SLC7A5 | Q01650 | 2/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | MMP1 | P03956 | 1/20 | 0.34 |
| ▸ | MMP2 | P08253 | 1/20 | 0.34 |
| ▸ | MMP3 | P08254 | 1/20 | 0.34 |
| ▸ | MMP9 | P14780 | 1/20 | 0.34 |
| ▸ | MMP8 | P22894 | 1/20 | 0.34 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.33 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | ACE | P12821 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12303664 | 0.87 | TSHR (0.39) | PKMTSHRUSP2MMP1MMP2 | |
| SCHEMBL12955470 | 0.75 | — | — | |
| SCHEMBL4972791 | 0.75 | — | — | |
| SCHEMBL2246459 | 0.75 | — | — | |
| SCHEMBL2246463 | 0.75 | — | — | |
| SCHEMBL10288542 | 0.73 | — | — | |
| Hydrochloric Acid SCHEMBL15792147 | 0.73 | — | — | |
| Hydrochloric Acid SCHEMBL22979248 | 0.73 | — | — | |
| Diethylamine SCHEMBL28600128 | 0.73 | TP53 (0.40) | SLC1A3SLC1A2SLC1A1SLC7A5GRIK1 | |
| Hydrochloric Acid SCHEMBL15792149 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1301519-B2 | PRODRUGS OF PHOSPHONATE NUCLEOTIDE ANALOGUES AND METHODS FOR SELECTING AND MAKING SAME | GILEAD SCIENCES INC (US) | 2021-11-10 | — | — | EP | disclosed |
| EP-3235823-A1 | PRODRUGS OF PHOSPHONATE NUCLEOTIDE ANALOGUES AND METHODS FOR SELECTING AND MAKING SAME | Gilead Sciences, Inc. (US) | 2017-10-25 | — | — | EP | disclosed |
| EP-2682397-B1 | Prodrugs of phosphonate nucleotide analogues and methods for selecting and making same | GILEAD SCIENCES INC (US) | 2017-04-19 | — | — | EP | disclosed |
| EP-1301519-B1 | PRODRUGS OF PHOSPHONATE NUCLEOTIDE ANALOGUES AND METHODS FOR SELECTING AND MAKING SAME | GILEAD SCIENCES INC (US) | 2015-02-25 | — | — | EP | disclosed |
| EP-2682397-A1 | Prodrugs of phosphonate nucleotide analogues and methods for selecting and making same | GILEAD SCIENCES, INC. (US) | 2014-01-08 | — | — | EP | disclosed |
| US-7803788-B2 | Prodrugs of phosphonate nucoleotide analogues | GILEAD SCIENCES, INC. (US) | 2010-09-28 | — | — | US | disclosed |
| US-20080227754-A1 | PRODRUGS OF PHOSPHONATE NUCLEOTIDE ANALOGUES | GILEAD SCIENCES, INC. | 2008-09-18 | — | — | US | disclosed |
| US-7390791-B2 | Which contain phosphoramidate linkages; for retroviral or hepadnaviral therapy; for treatment of HIV/aquired immunodeficiency syndrome; antitumor agents; improved bioavailability | GILEAD SCIENCES, INC. (US) | 2008-06-24 | — | — | US | disclosed |
| US-20060024659-A1 | Prodrugs of phosphonate nucleotide analogues and methods for selecting and making same | GILEAD SCIENCES, INC. | 2006-02-02 | — | — | US | disclosed |
| US-20050159392-A1 | Phosphoramidate linkages; retroviral or hepadnaviral therapy; tissue targeted therapy; HIV/aquired immunodeficiency syndrome; antitumor agents; improved bioavailability | BECKER MARK W (US) | 2005-07-21 | — | — | US | disclosed |
| US-20050124585-A1 | Prodrugs of phosphonate nucleotide analogues | BECKER MARK W (US) | 2005-06-09 | — | — | US | disclosed |
| US-20050124584-A1 | Prodrugs of phosphonate nucleotide analogues | BECKER MARK W (US) | 2005-06-09 | — | — | US | disclosed |
| US-20050124583-A1 | Novel mixed ester-amidates of 9-[2-(phosphonomethoxy)ethyl]adenine (PMPA) for retroviral or hepadnaviral target tissue therapy; viricides; antitumor and -carcinogenic agents; HIV; less toxicity to bystander tissues; greater potency of the parental drug; accumulation in lymphatic tissue | BECKER MARK W (US) | 2005-06-09 | — | — | US | disclosed |
| US-20050009043-A1 | Prodrugs of phosphonate nucleotide analogues | GILEAD SCIENCES, INC. | 2005-01-13 | — | — | US | disclosed |
| US-20040018150-A1 | Prodrugs of phosphonate nucleotide analogues and methods for selecting and making same | BECKER MARK W (US) | 2004-01-29 | — | — | US | disclosed |
| US-20030219727-A1 | Prodrugs of phosphonate nucleotide analogues | BECKER MARK W (US) | 2003-11-27 | — | — | US | disclosed |
| EP-1301519-A2 | PRODRUGS OF PHOSPHONATE NUCLEOTIDE ANALOGUES AND METHODS FOR SELECTING AND MAKING SAME | GILEAD SCIENCES, INC. (US) | 2003-04-16 | — | — | EP | disclosed |
| US-20020119443-A1 | Prodrugs of phosphonate nucleotide analogues and methods for selecting and making same | GILEAD SCIENCES, INC. | 2002-08-29 | — | — | US | disclosed |
| WO-2002008241-A2 | PRODRUGS OF PHOSPHONATE NUCLEOTIDE ANALOGUES AND METHODS FOR SELECTING AND MAKING SAME | GILEAD SCIENCES, INC. (US) | 2002-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050124583-A1 | Novel mixed ester-amidates of 9-[2-(phosphonomethoxy)ethyl]adenine (PMPA) for retroviral or hepadnaviral target tissue therapy; viricides; antitumor and -carcinogenic agents; HIV; less toxicity to bystander tissues; greater potency of the parental drug; accumulation in lymphatic tissue | PNP, PHOSPHO1, ENTPD1 | PKM 894/4885SLC1A3 2482/4885SLC1A2 3069/4885 |
| US-20050009043-A1 | Prodrugs of phosphonate nucleotide analogues | PNP, TYMP, APRT | PKM 1050/4885SLC1A3 1257/4885SLC1A2 1895/4885 |
| US-20050159392-A1 | Phosphoramidate linkages; retroviral or hepadnaviral therapy; tissue targeted therapy; HIV/aquired immunodeficiency syndrome; antitumor agents; improved bioavailability | SLC25A17, SLC25A1, SLC25A21 | PKM 1009/4885SLC1A3 807/4885SLC1A2 1772/4885 |
| US-20050124584-A1 | Prodrugs of phosphonate nucleotide analogues | PNP, TYMP, APRT | PKM 1050/4885SLC1A3 1257/4885SLC1A2 1895/4885 |
| US-20040018150-A1 | Prodrugs of phosphonate nucleotide analogues and methods for selecting and making same | PNP, PNPO, MTAP | PKM 767/4885SLC1A3 875/4885SLC1A2 1026/4885 |
| US-20080227754-A1 | PRODRUGS OF PHOSPHONATE NUCLEOTIDE ANALOGUES | PNP, TYMP, APRT | PKM 1050/4885SLC1A3 1257/4885SLC1A2 1895/4885 |
| US-20050124585-A1 | Prodrugs of phosphonate nucleotide analogues | PNP, TYMP, APRT | PKM 1050/4885SLC1A3 1257/4885SLC1A2 1895/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.